Evidence map›Paper›PMID 26713253›Full record

ArticlePeerJ2015

Establishing the role of honest broker: bridging the gap between protecting personal health data and clinical research efficiency.

Hyo Joung Choi, Min Joung Lee, Chang-Min Choi, JaeHo Lee, Soo-Yong Shin, Yungman Lyu, Yu Rang Park, Soyoung Yoo

Abstract read
In one paragraph

Article in PeerJ, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Elder Mistreatment Within Stroke Family Caregiving.Journal of applied gerontology : the official journal of the Southern Gerontological Society · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hyo Joung Choi *Office of Clinical Research Information, Asan Institute of Life Sciences, Asan Medical Center, Seoul, Korea.
Min Joung Lee *Office of Clinical Research Information, Asan Institute of Life Sciences, Asan Medical Center, Seoul, Korea.
Chang-Min ChoiOffice of Clinical Research Information, Asan Institute of Life Sciences, Asan Medical Center, Seoul, Korea.
JaeHo LeeOffice of Clinical Research Information, Asan Institute of Life Sciences, Asan Medical Center, Seoul, Korea.
Soo-Yong ShinOffice of Clinical Research Information, Asan Institute of Life Sciences, Asan Medical Center, Seoul, Korea.
Yungman LyuOffice of Clinical Research Information, Asan Institute of Life Sciences, Asan Medical Center, Seoul, Korea.
Yu Rang ParkDepartment of Biomedical Informatics, Asan Medical Center, Seoul, Korea.
Soyoung YooHuman Research Protection Center, Asan Institute of Life Sciences, Asan Medical Center, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background. The objective of this study is to propose the four conditions for the roles of honest brokers through a review of literature published by ten institutions that are successfully utilizing honest brokers. Furthermore, the study aims to examine whether the Asan Medical Center's (AMC) honest brokers satisfy the four conditions, and examine the need to enhance their roles. Methods. We analyzed the roles, tasks, and types of honest brokers at 10 organizations by reviewing the literature. We also established a Task Force (TF) in our institution for setting the roles and processes of the honest broker system and the honest brokers. The findings of the literature search were compared with the existing systems at AMC-which introduced the honest broker system for the first time in Korea. Results. Only one organization employed an honest broker for validating anonymized clinical data and monitoring the anonymity verifications of the honest broker system. Six organizations complied with HIPAA privacy regulations, while four organizations did not disclose compliance. By comparing functions with those of the AMC, the following four main characteristics of honest brokers were determined: (1) de-identification of clinical data; (2) independence; (3) checking that the data are used only for purposes approved by the IRB; and (4) provision of de-identified data to researchers. These roles were then compared with those of honest brokers at the AMC. Discussion. First, guidelines that regulate the definitions, purposes, roles, and requirements for honest brokers are needed, since there are no currently existing regulations. Second, Korean clinical research institutions and national regulatory departments need to reach a consensus on a Korean version of Limited Data Sets (LDS), since there are no lists that describe the use of personal identification information. Lastly, satisfaction surveys on honest brokers by researchers are necessary to improve the quality of honest brokers.

Indexed as

Honest brokerPatient health information protectionResearch efficiencySecondary use of clinical data

Identifiers

PMID26713253
PMCPMC4690386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.